In this paper, we report five cryo-EM structures of two well-recognized unimolecular agonists (tirzepatide and peptide 20) in complex with individual receptors and G s proteins
Safety and tolerability in the AD population were consistent with the known profile of semaglutide in other indications, with adverse events such as gastrointestinal symptoms and weight loss reflecting its established effects
Discussion Clinical trials have indicated that leptin administration failed as an efficient therapeutical approach to treat obesity 24,25,26 , although it attenuates the neuroendocrine and metabolic changes induced by weight loss 1,2,3,4,5
Jiang L, Huang J, Lu J, Hu S, Pei S, Ouyang Y
The most common side effects were mild-to-moderate gastrointestinal symptoms, which were dose-related and partially reduced with lower starting doses